Does Wegovy Reduce Cravings — and How Does That Actually Work?

You're thinking about Wegovy because food feels relentless, here's what changes

If you've spent years managing the constant background noise of cravings, the idea that a weekly injection could quieten it sounds too convenient. That scepticism makes sense. So it's worth being precise about what semaglutide actually does to the craving experience, rather than leaning on vague promises about appetite.

GLP-1 receptors exist throughout the body, including in the hypothalamus and reward-processing areas of the brain. Semaglutide activates those receptors, which shifts more than just how full you feel after eating. It also reduces the salience of food, the pull you feel toward a snack you aren't hungry for, the loop of thinking about what to eat next. Participants in the STEP 1 trial, published in the New England Journal of Medicine, showed an average 15% body-weight reduction over 68 weeks at the 2.4mg maintenance dose, and that result was built on top of meaningful reductions in how much participants wanted to eat in the first place. Weight loss at that scale is very hard to explain through stomach fullness alone.

For people exploring sugar cravings specifically, the experience is often that highly palatable foods lose some of their grip first, the biscuit you used to eat without thinking becomes less interesting, even if you could still eat it. That pattern is consistent with how reward-pathway modulation tends to work. It is not universal, and it does not mean cravings disappear entirely.

How long before the craving reduction actually kicks in

Treatment starts at 2.5mg, a dose chosen to help your body adjust, with the therapeutic effects building as the dose increases toward the 2.4mg maintenance level. For many people, some appetite shift is noticeable within the first few weeks, but the more reliable dampening of cravings tends to arrive once titration is under way.

This matters because people sometimes worry they're not responding during the early doses. The starter pen is doing its job of settling your system; it isn't the dose that shows you the full picture. Our guide on how semaglutide drives weight loss goes into the mechanism in more detail if you want the fuller picture on GIP, GLP-1 and what each does.

The titration schedule is set by your prescriber and described in your Patient Information Leaflet, and dose changes are not something to adjust independently. A prescriber will weigh up your response, any side effects, and your overall progress before recommending the next step. If cravings feel unchanged after several weeks at a given dose, that is exactly the kind of thing to raise with your clinical team rather than try to troubleshoot alone.

There is also a practical reality worth naming: some people find that cravings come back if a dose is missed or if treatment is paused. The research into semaglutide and POTS illustrates that this medicine interacts with physiology in ways that extend well beyond simple calorie balance, which is part of why ongoing clinical oversight matters throughout treatment.

What Wegovy won't do, and why that's useful to know before starting

Semaglutide reduces cravings for a lot of people. It does not eliminate the emotional, habitual or situational pull toward food. Stress eating, comfort eating, eating because it's what you always do at 9pm, the medicine quietens the biological signal, but those patterns have their own roots. Clinical guidance consistently frames Wegovy as part of a broader approach involving a reduced-calorie diet and increased activity, not a standalone fix. The NHS Better Health lose weight guidance covers what that lifestyle layer looks like in practice.

There is also some individual variation in how strongly people experience craving reduction. The majority of trial participants reported meaningful appetite suppression. Some notice a more modest effect. The factors driving that variation are still being studied. What is clear is that trying to judge your response based on the first few weeks, before titration is complete, gives an incomplete picture.

Common side effects during treatment are mostly gastrointestinal (nausea, constipation, loose stools) and they're most noticeable after starting or after each dose increase. They usually ease within a week or two. A fuller breakdown of what to expect is on our page on Wegovy's effects on body composition, which puts these factors in context. If you want to read across the full treatment landscape before deciding anything, the Wegovy overview brings it together in one place.

If you're considering starting, the clinical route matters

Wegovy is a prescription-only medicine. A prescriber assesses your health history, current medications and BMI before it can be issued, that process protects you, partly because there are conditions and medications where semaglutide requires specific discussion or is not appropriate. For a clear view of who qualifies and what the assessment looks at, our weight-loss treatment overview covers eligibility criteria without jargon.

If you've already been researching whether Wegovy helps with cravings from different angles, you probably have a reasonable idea of whether this might be relevant for you. The next practical step is a consultation. At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not software) on the same day you complete it. There are no hidden fees: consultation, prescription, and next-working-day delivery are included in one price.

If you'd like to find out whether you're clinically suitable, check your eligibility and our prescribers will take it from there.